Release date- 22082019 - INDIANAPOLIS - A Chicago-based arbitration panel has ruled in favor of Eli Lilly and Company
(NYSE: LLY) in a claim filed by Adocia S.A.
9, 2019 /PRNewswire/ - Eli Lilly and Company
(NYSE: LLY) today announced that the U.S.
US-based drugmaker Eli Lilly and Company
(NYSE: LLY) has entered into an agreement to sell the rights in China for two legacy Lilly antibiotic medicines, Ceclor and Vancocin, as well as a manufacturing facility in Suzhou, China that produces Ceclor, to Eddingpharm, a China-based specialty pharmaceutical company, the company said.
Eli Lilly and Company
(NYSE: LLY), a global healthcare company, announced on Friday that it has completed its acquisition of Loxo Oncology Inc.
Healthcare company Eli Lilly and Company
(NYSE:LLY ) reported on Thursday the election of Anne White as its senior vice president and president of its Lilly Oncology.
In late January, Trump (http://www.chicagotribune.com/business/ct-trump-drugmakers-price-controls-20170131-story.html) met with a collection of CEOs from the top pharmaceutical companies, including David Ricks, the former CEO and current chairman of the Indiana-based Eli Lilly and Company
. Drug companies have increased their lobbying presence this year to ward off legislation that would hurt their profits.
Currently, raloxifene in the Chinese market are monopolized by the following three companies: Eli Lilly and Company
(Spain), Eli Lilly and Company
(UK) and Jiangsu Hengrui Medicine Co., Ltd, among which Eli Lilly and Company
(Spain) has the largest market share of 86% for sales value in 2014.
[ClickPress, Tue Jul 28 2015] Global Markets Direct's, 'Eli Lilly and Company
- Product Pipeline Review - 2015', provides an overview of the Eli Lilly and Company
's pharmaceutical research and development focus.
Eli Lilly and Company
(NYSE: LLY) said it has commenced a cash tender offer for up to USD1.6 billion aggregate principal amount of specified series of its outstanding debt.
Pharmaceutical products company Eli Lilly and Company
(NYSE:LLY) and pharmaceutical company Boehringer Ingelheim announced on Monday that the European Medicines Agency (EMA) has accepted and will review their marketing authorisation application (MAA) for LY2963016, an investigational basal (long-acting) insulin for the treatment of type 1 and type 2 diabetes,
Amin Hussain Al Amiri, Assistant Undersecretary for Medical Practice and License Sector at the UAE Ministry of Health, recently inaugurated Eli Lilly and Company
's new regional headquarters for Turkey, Middle East, Africa, Russia and the CIS (TMEA-CIS) in Dubai Healthcare City, UAE.